Class / Patent application number | Description | Number of patent applications / Date published |
424487000 | Acrylic acid and derivatives | 83 |
20080206338 | CONTROLLED RELEASE FORMULATIONS OF AN ALPHA-ADRENERGIC RECEPTOR ANTAGONIST - The present invention relates to controlled release formulations comprising an alpha-adrenergic receptor antagonist. More particularly, the present invention relates to controlled release matrix formulation comprising alfuzosin hydrochloride and a combination of hydrophilic and hydrophobic polymers prepared by direct compression. | 08-28-2008 |
20080206339 | VERY-PURE SUPERPOROUS HYDROGELS HAVING OUTSTANDING SWELLING PROPERTIES - The invention relates to methods for preparing superporous hydrogels (SPH) that are very-pure and have desirable swelling properties necessary for commercial use, such as in food and pharmaceutical applications. Such methods include simultaneous use of low and high glass transition monomers to improve impurity and swelling profiles of the SPH, use of an integration means to prepare a very homogenous superporous hydrogel foam, washing the superporous hydrogel in a washing solution comprising different ratios of solvent to non-solvent (e.g., water/alcohol), use of a chemically-induced expansion/contraction process to enhance the efficiency of the multiple washing process and to fully structuralize the SPH, and employing one or more separation techniques, such as rubbing, filtration, centrifugation, compression and cutting to increase the efficiency of the purification process and to enhance the SPH swelling properties. | 08-28-2008 |
20080220067 | ANTIMICROBIAL ADHESIVE SYSTEM - An adhesive composition having dispersed therein a broad spectrum antimicrobial agent for use in medical applications, such as an adhesive for surgical drapes, wound dressings and tapes, is provided. The adhesive is composed of acrylic polymers, tackifiers and a preferred antimicrobial agent, diiodomethyl-p-tolylsulfone. The subject adhesive composition may be formulated as either an essentially solventless hot melt, or as a solvent based system wherein an emulsion of the antimicrobial agent and the removal of excess solvent is avoided. | 09-11-2008 |
20080241249 | Cyanoacrylate composite - An adhesive composite composition is provided including one or more polymerizable monomers and one or more metal stearates. The one or more polymerizable monomers may be a cyanoacrylate monomer. The adhesive composite composition may further comprise a plasticizer, an initiator, a rate modifier, a stabilizer, a colorant, a heat dissipating agent, or other additives. Methods for the application of the adhesive composite compositions to living tissue are also provided. The adhesive composite composition provides an adhesive composite material upon polymerization which is a polymer matrix entrapping the metal stearate. Polymerization of the adhesive composite composition at a site on living tissue provides an adhesive composite material which promotes microcirculation and tissue growth at the site of application of the adhesive composite composition. | 10-02-2008 |
20080260835 | PHARMACEUTICAL COMPOSITIONS FOR POORLY SOLUBLE DRUGS - The present invention provides a pharmaceutical composition of a practically insoluble drug, wherein the composition may be administered with food or without food. The composition may be in the form of a solid dispersion of the practically insoluble drug and a polymer having acidic functional groups, and the composition may in vitro form a suspension. | 10-23-2008 |
20080292708 | Polymeric Adhesive Matrix with Salified Carboxylic Groups for Transdermal Use - Polymeric matrices for the controlled release of medicaments for the topical transdermal use comprising copolymers of acrylic and/or methacrylic acid or esters thereof having a Tg lower than 0° C., whose free carboxy groups are salified with compatible organic or inorganic bases. The matrices of the invention allow to prepare therapeutical systems for the controlled-release of active principles through the transdermal route, thus solving stability, solubility and/or bioavailability problems of the active ingredient within the matrix. | 11-27-2008 |
20090028946 | Photo-responsive delivery system - A photo-responsive delivery system useful to deliver a compound to a target site is provided. The system includes a physiologically compatible matrix crosslinked with a photo-responsive matrix cross-linking agent. A method of making the delivery system and a method of delivering a compound to a target site using the system are also provided. | 01-29-2009 |
20090110734 | QUATERNISED AMMONIUM CYCLODEXTRIN COMPOUNDS - Use of a compound of formula (I): | 04-30-2009 |
20090117191 | Controlled release tramadol formulations - A controlled release preparation for oral administration contains tramadol, or a pharmaceutically acceptable salt thereof, as active ingredient. | 05-07-2009 |
20090117192 | COMPOSITION FOR TRANSDERMAL ABSORPTION AND FORMULATION COMPRISING A POLYMERIC MATRIX FORMED THEREFROM - The inventive composition for transdermal absorption characterized by comprising a nonsteroidal anti-inflammatory drug as an active ingredient together with an alkali metal-containing alcohol derivative as a solubilizing agent for the active ingredient comprises a high concentration of the active ingredient while using only a small amount of the solvent, and a transdermal absorption formulation comprising a polymeric matrix formed from the composition is capable of maximizing the skin absorption of the active ingredient with minimal skin irritation. | 05-07-2009 |
20090136575 | Protein Formulation - The present invention relates to a new and improved low-concentration formulation of an active enamel substance, such as an enamel matrix, enamel matrix derivative and/or an enamel matrix protein, intended to be used as therapeutic, as propylacetic and/or as cosmetic agent. In the present invention, said active enamel substance is incorporated into a polymeric matrix, which is either suitable for cellular in-growth, or cell-occlusive. The active enamel substance can be incorporated into the polymeric matrix so that it is released by degradation of the polymeric matrix, by enzymatic action and/or by diffusion. Comprised in the invention is thus in particular a new pharmaceutical and/or cosmetic formulation of an active enamel substance at a lower total concentration within the formulation, wherein a spatial and/or selective regulation of release of said active enamel substance permits a greater percentage of the active enamel substance to be released at the time of appropriate cellular activity. | 05-28-2009 |
20090191271 | Topical Formulations - Saturated, monophasic solutions of drug in a solvent and propellant mixture, together with a film-forming agent, exhibit transdermal diffusion fluxes greater than those predicted by Fick's law when applied topically. | 07-30-2009 |
20090208579 | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same - A matrix type sustained-release preparation and a manufacturing method therefor are provided wherein dissolution with low pH dependence of a basic drug or a salt thereof at the early stage of dissolution can be ensured in a dissolution test, and wherein as the dissolution test proceeds, a ratio of a dissolution rate of the basic drug or the salt thereof in an acidic test solution to a dissolution rate of the basic drug or the salt thereof in a neutral test solution (dissolution rate in the acidic test solution/dissolution rate in the neutral test solution) decreases with dissolution time at the late stage of dissolution, as compared to the early stage of dissolution. According to the present invention, the matrix type sustained-release preparation contains a basic drug or a salt thereof and at least one enteric polymer, in which solubility of the basic drug or the salt thereof in a 0.1 N hydrochloric acid solution and a neutral aqueous solution, pH 6.0 is higher than in a basic aqueous solution, pH 8.0. | 08-20-2009 |
20090220607 | POLYMERIC COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF - Described herein are polymeric compositions having a polymer residue and a crosslinker residue, wherein the polymer residue is bonded to the crosslinker residue with a moiety formed from a cycloaddition reaction. Also, described are methods of making and using such polymeric compositions. | 09-03-2009 |
20090238875 | Chitosan or Hyaluronic Acid-Poly(Ethylene Oxide)-and Chitosan-Hyaluronic Acid-Poly(Ethylene Oxide)-Based Hydrogel and Manufacturing Method Therefor - Disclosed are a chitosan-chitosan-polyethylene oxide hydrogel formed via covalent bonding between chitosan derivatives crosslinked with an acrylate or methacrylate functional group-containing substance and a thiol functional group-containing substance and hydrogel microbeads thereof; a hyaluronic acid-hyaluronic acid-polyethylene oxide hydrogel formed via covalent bonding between hyaluronic acid derivatives crosslinked with an acrylate or methacrylate functional group-containing substance and a thiol functional group-containing substance and hydrogel microbeads thereof; and a chitosan-hyaluronic acid-polyethylene oxide hydrogel formed via covalent bonding between a chitosan derivative crosslinked with a (meth)acrylate functional group-containing substance as well as a hyaluronic acid derivative crosslinked with a (meth) acrylate functional group-containing substance and a thiol functional group-containing substance and hydrogel microbeads thereof. | 09-24-2009 |
20090269406 | Therapeutic uses of biocompatible biogel compositions - The present invention relates to biocompatible biogel compositions and methods of drug delivery. The biocompatible biogel is a physical polymer matrix formed via affinity interactions between its components. The components of the biocompatible biogel comprise a cationic component, an anionic component, and optionally a therapeutic agent. | 10-29-2009 |
20090280183 | MULTIPARTICULATE FORM OF ADMINISTRATION, COMPRISING NUCLEIC ACID-CONTAINING MUCOADHESIVE ACTIVE INGREDIENTS, AND METHOD FOR PRODUCING SAID FORM OF ADMINISTRATION - The invention relates to an oral, multiparticulate form of administration, comprising pellets in the size ranging from 50 to 2500 $g(m)m which are substantially constituted of a) an inner matrix layer containing nanoparticles that contain a nucleic acid active ingredient and being embedded in a matrix of a polymer having a mucoadhesive effect, and b) an outer film coating, substantially consisting of an anionic polymer or copolymer that is optionally formulated with pharmaceutically conventional adjuvants, especially emollients. | 11-12-2009 |
20090317473 | CONTROLLED-RELEASE FORMULATIONS, METHOD OF MANUFACTURE, AND USE THEREOF - The present invention includes a controlled-release composition having a matrix. The matrix contains a pharmaceutically effective amount of an active agent or a pharmaceutically acceptable salt, solvate, ester, and/or prodrug thereof, an ionic non-gelling matrix polymer, and a pH modifier. The ionic non-gelling matrix polymer is practically insoluble and unswellable at a first aqueous fluid pH and is soluble at a second aqueous fluid pH. The pH modifier is present in an amount to control the release of the active agent from the composition. The controlled-release composition is substantially free of a gelling or swellable excipient. The present invention also provides methods of making and using the controlled-release compositions. | 12-24-2009 |
20090317474 | USE OF POLYETHYLENE GLYCOL IN INFLAMMATION RELATED TOPICAL DISORDERS OR DISEASES AND WOUND HEALING - The present invention relates to hydrogel compositions or aqueous solutions comprising one or more forms of Poly-ethylene Glycol, for use as medicaments, more particularly for topical application in the treatment of wounds, for the treatment of inflammatory skin disease and in particular for the prevention of scar formation and/or for enhancing the repair of damaged skin or mucosa. | 12-24-2009 |
20090324722 | CARTILAGE FILLING DEVICE - Compositions and methods for treating a tissue defect. | 12-31-2009 |
20100003328 | BONE FILLER FOR CARTILAGE TISSUE REGENERATION TREATMENT - It is intended to provide a medical material which enables a new method for cartilage tissue regeneration treatment based on an entirely new concept unlike a treatment method by transplantation of autologous cartilage tissue, a cartilage alternative or undifferentiated cells. The invention provides a bone filler for cartilage tissue regeneration comprising hydrogel having an interpenetrating network structure formed by two or more crosslinked network polymers or a semi-interpenetrating network structure formed by a crosslinked network polymer and a linear polymer. By filling the bone filler of the invention in a hole or a groove provided in subchondral bone just under damaged cartilage tissue, regeneration of the cartilage tissue or both the cartilage tissue and the subchondral bone can be promoted. | 01-07-2010 |
20100003329 | BIOLOGICAL ADHESIVE - Biologically compatible polymers carry at least two different kinds of functional groups. Adhesive formulations include a biologically compatible adhesive, which can be used with a bridging molecule. | 01-07-2010 |
20100008991 | Transdermal estrogen device and delivery - Described are transdermal drug delivery systems for the transdermal administration of estrogen, comprising a polymer matrix and estrogen. Methods of making and using such systems also are described. | 01-14-2010 |
20100028436 | POLYMER MATRIX, USES THEREOF AND A METHOD OF MANUFACTURING THE SAME - The present invention relates to a polymer matrix, characterized in that it comprises a) an electron donating constituent and b) metal particles comprising at least one metal chosen from palladium, gold, ruthenium, rhodium, osmium, iridium, and platinum. The polymer matrix makes it possible to improve the biocompatibility and antimicrobial properties of substrates coated with said polymer matrix. | 02-04-2010 |
20100040690 | Adhesive mixture for transdermal delivery of highly plasticizing drugs - Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs. | 02-18-2010 |
20100068280 | SUSTAINED RELEASE PHARMACEUTICAL DOSAGE FORM CONTAINING PHENYLEPHRINE - Pharmaceutical compositions comprising phenylephrine in a sustained release oral dosage formulation. Compositions can comprise phenylephrine alone or phenylephrine in combination additional pharmaceutically active substances such as an antihistamine and/or an analgesic. | 03-18-2010 |
20100086599 | ORAL MODIFIED RELEASE FORMULATIONS - This invention is directed to an oral modified release formulation of the phytoestrogen 8-Prenylnaringenin in combination with a progestin, preferably with Drospirenone, and several uses thereof. In another aspect of the invention an oral modified formulation of 8-Prenylnaringenin with an immediately releasing progestin, like Drospirenone, is provided as well as several uses thereof. | 04-08-2010 |
20100119607 | BIOENHANCED COMPOSITIONS - The present invention relates to the method of increasing the bioavailability of Angiotensin II Receptor Blockers (ARBs) by preparing a composition of an ARB with at least one solubility enhancing agent. The invention is particularly focused to provide a novel or modified dissolution profile where the release of ARB in the GI tract is independent of physiological pH conditions. | 05-13-2010 |
20100143478 | TREATMENT OF INFLAMMATION AND THE COMPLEMENT AND KININ CASCADES IN A PATIENT, PARTICULARLY IN CHRONIC ULCEROUS SKIN LESIONS - The invention provides methods of inhibiting inflammation and/or the complement cascade and/or the kinin cascade in a human or non-human animal patient, particularly in a wound (for example, a chronic ulcerous skin lesion) in a human or non-human mammal (particularly a human). The affected location of the patient is contacted with a hydrogel composition comprising a hydrophilic polymer carrying multiple pendant sulphonyl groups, optionally with multiple pendant carboxylic groups, on each polymer molecule. | 06-10-2010 |
20100159011 | Compositions For Biomedical Applications - The invention relates to composite materials that contain a polymer matrix and aggregates, and in some embodiments, methods of making, and methods of using these materials. Preferably, the aggregates are calcium phosphate aggregates. Preferably, the material is resistant to fracture. In further embodiments, the materials are used in surgical procedures of bone replacement. In further embodiments, the materials contain polyhedral silsesquioxanes and/or biodegradable segments. In further embodiments, the polymer matrix comprises biomolecules. | 06-24-2010 |
20100166867 | Novel administration form of osteogenic protein complexes - The invention relates to osteogenic compositions composed of a coprecipitate that contains at least one insoluble calcium salt and at least one complex between an osteogenic protein and a polysaccharide, said coprecipitate being in divided form. The invention also relates to kits for performing the invention. | 07-01-2010 |
20100178345 | Hydrogel Microparticle Composition, Application Thereof and Method for Preparing the Same - Disclosed herein is a method for preparing a hydrogel microparticle composition. A dispersion including 1 part by weight of N-isopropyl acrylamide, about 0.1-0.5 part by weight of chitosan, about 0-0.05 part by weight of N,N′-methylene bisacrylamide, about 0.1-0.5 part by weight of glacial acetic acid, and about 20-40 parts by weight of water is prepared. About 0.01-0.3 part by weight of an anionic initiator is added into the dispersion and the dispersion is allowed to undergo a polymerization reaction at a temperature of about 10-100° C. for about 1 to 5 hours, thereby producing a plurality of hydrogel microparticles dispersed in the water to form the hydrogel microparticle composition. | 07-15-2010 |
20100196481 | SPINAL CORD INJURY, INFLAMMATION, AND IMMUNE-DISEASE: LOCAL CONTROLLED RELEASE OF THERAPEUTIC AGENTS - A drug delivery system is provided for treatment of oxidative stress. The drug delivery system can include a therapeutic agent and a matrix. The therapeutic agent can include an antioxidant or steroid. The matrix can include a hydrogel, particle, microparticle, or nanoparticle. A method of treating injury, including peripheral nerve injury or spinal cord injury, is also provided. The method includes injecting the drug delivery system at the site of injury. | 08-05-2010 |
20100196482 | POLYMER-ENCAPSULATED REVERSE MICELLES - A method for encapsulating nucleic acids, particularly siRNAs, shRNAs, microRNAs, gene therapy plasmids, and other oligonucleotides in biodegradable polymers is disclosed, whereby the nucleic acids are formulated into reverse micelles composed of non-toxic and/or naturally-occurring lipids prior to nanoparticle formation by nanoprecipitation. This method can be coupled to other techniques that improve intracellular drug targeting, ultimately enhancing intracellular delivery of the aforementioned nucleic acids. | 08-05-2010 |
20100203142 | AMPHIPHILIC COMPOUND ASSISTED NANOPARTICLES FOR TARGETED DELIVERY - The present invention generally relates to nanoparticles with an amphiphilic component. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries. | 08-12-2010 |
20100215747 | NANOPARTICLES COMPRISING IONIZABLE, POORLY WATER SOLUBLE CELLULOSIC POLYMERS - A pharmaceutical composition comprises nanoparticles comprising ionizable, poorly water soluble cellulosic polymers. | 08-26-2010 |
20100215748 | FUNCTIONALIZED ADHESIVE MEDICAL GEL - A bioadherent substrate includes a medical gel or medical gel precursor having a plurality of reactive members of a specific binding pair attached on or adapted to be attached to a surface of the medical gel, said reactive members being capable of forming covalent bonds with a plurality of complementary reactive members of the specific binding pair via a reaction selected from a Huisgen cycloaddition reaction, a Diels-Alder reaction and a thiol-ene reaction. A method for adhering a medical gel to biological tissue includes providing a medical gel or a medical gel precursor having a plurality of reactive members of a specific binding pair attached on or adapted to be attached to a surface of the medical gel and providing tissue with a plurality of complementary reactive members of the specific binding pair, wherein upon contact of the reactive members on the medical gel with the complimentary reactive members on the tissue, covalent bonds are formed between the reactive members and the complementary reactive members, thus adhering the medical gel to the tissue. | 08-26-2010 |
20100215749 | TEMPERATURE- AND pH-RESPONSIVE POLYMER COMPOSITIONS - Temperature- and pH-responsive copolymer compositions, and drug delivery devices, conjugates, nanoparticles, and micelles that include the compositions. | 08-26-2010 |
20100233265 | MATRIX-TYPE PHARMACEUTICAL SOLID PREPARATION - The present invention aims to provide a matrix-type solid preparation that has high-level release controllability for suppressing drug release in the upper gastrointestinal tract and accelerating drug release in the lower gastrointestinal tract, and that solves of all the above drawbacks caused by combining a plasticizer. The present invention provides a matrix-type pharmaceutical solid preparation that contains: (a) a methacrylic acid-based enteric polymer; and (b) a sugar and/or a sugar alcohol, wherein 1 g of the sugar and/or the sugar alcohol can be dissolved in not more than 4 g of water at a water temperature of 20 to 25° C. | 09-16-2010 |
20100239672 | LAYER SILICATE NANOCOMPOSITES OF POLYMER HYDROGELS AND THEIR USE IN TISSUE EXPANDERS - The invention relates to nanocomposites comprising of (i) hydrogels synthetized by copolymerization of N-isopropylacrylamide and/or acrylamide and/or acrylic acid monomers and of (ii) layer silicates, and to the process for preparing them. The invention covers osmotically active hydrogel expanders containing said nano-composites, suitable for tissue expansion and the use of said materials for obtaining live skin. | 09-23-2010 |
20100255099 | CLAVULANATE FORMULATION FOR NEUROPROTECTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS - The present invention generally relates to use of a stable solid pharmaceutical compositions that includes a clavulanate as the pharmaceutically active ingredients in an immediate-release or an extended-release solid dosage form. The composition can be used in a method of treating a neurodegenerative disease, providing neuroprotection, or preventing neuronal cell loss or death. Exemplary neurodegenerative diseases include Parkinson's disease, Alzheimer's disease and multiple sclerosis. | 10-07-2010 |
20100260850 | Controlled Release Devices and Methods for Delivery of Nucleic Acids - Embodiments of the invention include devices and methods for the delivery of nucleic acids. In an embodiment the invention includes a controlled release device including a polymeric matrix and a nucleic acid delivery construct disposed within the polymeric matrix. The nucleic acid delivery construct can include a nucleic acid molecule and a peptide molecule. The nucleic acid delivery construct can be configured to exhibit elution properties of a peptide from the polymeric matrix. The polymeric matrix can be configured to elute the nucleic acid delivery construct. Other embodiments are included herein. | 10-14-2010 |
20100266691 | Agents and Methods to Stimulate Bone Healing - An agent for stimulating bone healing including isolated lysophosphatidic acid (LPA) and a hydrogel. A method of enhancing bone healing including identifying a damaged area of a bone and administering an agent comprising lysophosphatidic acid (LPA) is administered to the damaged area of the bone. A method of increasing bone regrowth. A subject is identified having a bone injury and lysophosphatidic acid (LPA) is administered to the subject. | 10-21-2010 |
20100272810 | Delivery System for Binding and Release of Growth Factors - The present invention provides a polymer delivery system for the in vivo binding and release of growth factors, preferably orthobiologic GF, comprising a hyperbranched polymer having physiologically-acceptable anionic phosphorous groups. The hyperbranched polymer is preferred to be a polyurea with phosphonate anions. This polymer can be cross-linked to form a network and provide a coating for implanted devices. | 10-28-2010 |
20100278917 | Formulations and Methods of Treating Inflammatory Bowel Disease - Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid to affected areas of the intestine. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis. | 11-04-2010 |
20100285133 | TRANSDERMAL DRUG DELIVERY SYSTEM CONTAINING GRANISETRON - Disclosed herein is a transdermal system in a matrix form capable of enhancing granisetron carrying efficiency and improving transdermal absorption while inhibiting recrystallization, which comprises: at least one transdermal enhancer selected from a group consisting of polyglyceryl-3 oleate, polyethyleneglycol-20 almond glyceride, polyethyleneglycol-12 palm kernel glyceride, isopropyl myristate and oleyl alcohol; and an acrylate polymer. | 11-11-2010 |
20100291216 | PHARMACEUTICAL COMPOSITIONS - The present invention relates to pharmaceutical compositions for sustained release comprising a water soluble salt of the HMG-CoA reductase inhibitor fluvastatin as active ingredient, said composition being selected from the group comprising matrix formulations, diffusion-controlled membrane coated formulations; and combinations thereof. | 11-18-2010 |
20100291217 | PHARMACEUTICAL COMPOSITIONS - The present invention relates to pharmaceutical compositions for sustained release comprising a water soluble salt of the HMG-CoA reductase inhibitor fluvastatin as active ingredient, said composition being selected from the group comprising matrix formulations, diffusion-controlled membrane coated formulations; and combinations thereof. | 11-18-2010 |
20100316722 | Pharmaceutical Forms for the Release of Active Compounds - Pharmaceutical form containing at least an active compound and a polymeric matrix, wherein said polymeric matrix comprises at least one polymer of cationic nature and at least one biodegradable polymer, process for the preparation thereof, pharmaceutical formulations comprising said pharmaceutical form, and their uses. The pharmaceutical form provides enhanced absorption of active compounds across the mucosa. | 12-16-2010 |
20100323015 | MODIFIED RELEASE FORMULATION AND METHODS OF USE - A modified release pharmaceutical formulation includes about 30-70% N-(2-amino-4-(fluorobenzylamino)-phenyl) carbamic acid ethyl ester (retigabine), or a pharmaceutically acceptable salt, solvate or hydrate thereof, about 5-30% of a drug delivery matrix including hydroxypropylmethylcellulose (HPMC), and an enteric polymer. The pharmaceutical formulation produces a sustained plasma concentration of retigabine following administration to a subject for 4-20 hours longer than the time required for in vitro release of 80% of retigabine. The plasma concentration vs. time profile of this formulation is substantially flat over an extended period lasting for about 4 hours to about 36 hours. A method of treating a disorder characterized by nervous system hyperexcitability includes administering to a subject an effective amount of these pharmaceutical formulations. | 12-23-2010 |
20110027369 | PHARMACEUTICAL COMPOSITION IN THE FORM OF A HYDROGEL FOR TRANSDERMAL ADMINISTRATION OF ACTIVE INGREDIENTS - The invention relates to a pharmaceutical composition in the form of a hydrogel that comprises a carboxylic acid diester, a C | 02-03-2011 |
20110059176 | MATERIAL FOR PREVENTING TISSUE ADHESION AND MATERIAL FOR PREVENTING JOINT CONTRACTURE - The present invention provides a tissue adhesion prevention material preparable at an affected area at the time of surgical procedure by producing a three-dimensional polymeric structure having a flexible structure and high solute permeability in a medium comprising water as the main component under mild conditions appropriate for body tissue components (i.e., at ordinary temperature and pressure) without conducting a chemical reaction or employing a physical procedure such as heating or light or radiation irradiation. This makes it possible to provide a tissue adhesion prevention material and a joint contracture prevention materials, which can effectively prevent postoperative adhesion of a tissue in the affected area to the surrounding tissue and contracture of the movable part of a joint. | 03-10-2011 |
20110086102 | DELAYED RELEASE COMPOSITIONS - The present invention provides delayed release pharmaceutical compositions comprising an active pharmaceutical ingredient, e.g. mycophenolate sodium, and an enteric polymer, and methods for preparing the same. Preferably, the pharmaceutical compositions do not contain a coating. | 04-14-2011 |
20110091555 | Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant in the manufacture of a medicament for treating female genital disorders. - A hydrophilic matrix is disclosed which comprises: | 04-21-2011 |
20110104283 | COMPOSITIONS AND METHODS OF NATURAL PRODUCTS IN NANOFORMULATIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS - A composition and method for treating a bone condition of an animal. The composition includes a nanoformulation of active ingredients. The active ingredients include | 05-05-2011 |
20110111033 | HYDROGEL WITH COVALENTLY CROSSLINKED CORE - A novel hydrogel system is provided. The hydrogel system comprises a biocompatible hydrogel core having dispersed therein a covalently crosslinked polymer matrix. The hydrogel system is useful per se or as an encapsulation system. | 05-12-2011 |
20110111034 | METHOD AND MATERIAL FOR ENHANCED TISSUE-BIOMATERIAL INTEGRATION - The present invention relates to the covalent binding of a hydrogel to an extracellular matrix (ECM). The integration of the hydrogel with the tissue is superior to that in previous techniques. Moreover, unlike previous techniques, the present invention does not require a photoinitiator. Potential therapeutic applications include tissue repair and delivery of drugs or cells. | 05-12-2011 |
20110129535 | TRANSDERMAL TESTOSTERONE DEVICE AND DELIVERY - Described are transdermal drug delivery systems for the transdermal administration of testosterone, comprising a polymer matrix and testosterone. Methods of making and using such systems also are described. | 06-02-2011 |
20110135732 | MULTIPLE PHASE CROSS-LINKED COMPOSITIONS AND USES THEREOF - The present invention is directed to pharmaceutical compositions, and method for preparing pharmaceutical compositions, comprising a cross-linked matrix physically entrapping at least one therapeutic agent. The matrix may comprise one or more phases in addition to an aqueous phase, such as a solid and/or oil phase. The matrix of the invention has at least one controlled release in-vivo kinetic profile, and may have additional profiles for the same agent. The matrix may also comprise more than one therapeutic agent, and each additional therapeutic agent may have one or more controlled release in-vivo kinetic profile. | 06-09-2011 |
20110151006 | STIMULI-RESPONSIVE HYDROGEL - The present invention relates to a hydrogel comprising a polymer, a first polypeptide and a polypeptide binding partner, wherein the polypeptide binding partner is a second polypeptide, a nucleic acid or a small molecule, and wherein the interaction between the first polypeptide and the polypeptide binding partner stabilizes the hydrogel and is modulated by the addition of a modulating compound. A drug may be physically entrapped in the hydrogel, bound to the polymer forming the hydrogel structure, or bound to the first polypeptide or the polypeptide binding partner, and then be set free on addition of the modulating compound. Such a hydrogel comprising a drug may be injected into a patient, and drug release modulated by orally administering the modulating compound. | 06-23-2011 |
20110171308 | PH-SENSITIVE SOLID PHARMACEUTICAL COMPOSITION FOR ORAL PREPARATION AND PREPARATION METHOD THEREOF - A pH-sensitive solid pharmaceutical composition for oral formulation and preparation method thereof is provided. The solid pharmaceutical composition contains a pharmaceutical active ingredient, a nano-matrix carrier and a pH-sensitive polymer material. | 07-14-2011 |
20110171309 | Compositions and Methods for Composite Nanoparticle Hydrogels - Provided herein are systems, methods, and compositions for composite nanoparticle hydrogel networks and systems responsive to a first temperature. | 07-14-2011 |
20110200675 | DRUG DELIVERY VEHICLES, METHODS OF MANUFACTURE, AND METHODS OF USE THEREOF - Drug delivery vehicles that release one or more drugs, e.g., an opioid antagonist and/or an opioid, in response to changes in the chemistry of body fluids, specifically in response to changes in the partial pressure of CO | 08-18-2011 |
20110206769 | ORAL ANTIDEPRESSANT FORMULATION WITH REDUCED EXCIPIENT LOAD - Provided are methods for reducing the excipient load of pharmaceutical formulations containing 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide as the active pharmaceutical ingredient, and compositions related thereto. In particular, provided is a pharmaceutical product comprising 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide and a stabilizer admixed throughout a solid-form unilamellar matrix, wherein the ratio of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide to stabilizer ranges from about 2:3 to about 1:10, and related methods of forming the pharmaceutical product. | 08-25-2011 |
20110229572 | DELIVERY OF DRUG COMBINATIONS - A composition comprising microspheres of a polymer matrix, having two different pharmaceutical actives having complementary, usually synergistic, activity in killing cells. The compositions have particular utility for treating tumours. Useful combinations are doxorubicin with rapamycin, irinotecan with ibuprofen, ibuprofen with doxorubicin and irinotecan with doxorubicin. The polymer matrix is preferably a crosslinked polyvinyl alcohol. The drugs may be included in the same microsphere, or microspheres each with an individual pharmaceutical agent may be mixed together. The microspheres are preferably used in chemoembolisation of tumours. | 09-22-2011 |
20110287102 | CHAIN EXTENDERS - The present invention relates to chain extenders, processes for their preparation and their use in the preparation of biocompatible biodegradable polyurethanes and polyurethane ureas for biomedical applications such as stents, scaffolds for tissue engineering. | 11-24-2011 |
20110293721 | PIROXICAM-CONTAINING MATRIX PATCHES AND METHODS FOR THE TOPICAL TREATMENT OF ACUTE AND CHRONIC PAIN AND INFLAMMATION THEREWITH - This invention relates to matrix patches for the topical (i.e., transdermal) delivery of piroxicam and methods for the treatment of acute and chronic pain and inflammation therewith, particularly pain and inflammation caused by sports injuries or other muscle aches or injuries requiring the application of analgesic and/or anti-inflammation medication, in this instance, piroxicam. | 12-01-2011 |
20120003316 | TRANSMUCOSAL DELIVERY SYSTEM - This invention relates to a multi-configured, transmucosal pharmaceutical dosage form and, more particularly, to a pharmaceutical dosage form which has a single monolithic/heterogeneous layer or a plurality of such layers. The dosage form is suitable for the delivery of one or more pharmaceutical compositions via the buccal, sublingual, rectal, vaginal or transmucosal delivery route in a human or animal body. It provides for selected delivery profiles resulting from, but not limited to, a porosity-enabled composite matrix of one or more layers/components of the pharmaceutical composition/s. The invention also provides for a method of manufacturing said transmucosal pharmaceutical dosage form in a plurality of configurations. | 01-05-2012 |
20120015034 | TEMPERATURE SENSITIVE POLYMERS - The present invention relates to compositions comprising polymers whose solubility characteristics can be changed by incubation and particularly poly (hydroxyalkyl(meth) acrylamide mono/di-lactate interpolymers. Another aspect of this invention is the application of such temperature sensitive polymers as release systems of biologically active compounds. The polymers of the present invention comprise monomers, which have modifiable functionality. The functionality of the monomers can for example be modified by the presence of hydrolysable groups. The modification is effected by the incubation, leading to a change of the water solubility characteristics of the polymer. The polymers used in the present invention contain hydrolysable chemical groups. As a result the polymer's solution characteristics, specifically its lower critical solution temperature (LCST), change upon incubation. | 01-19-2012 |
20120040002 | RESORBABLE AND BIOCOMPATIBLE FIBRE GLASS COMPOSITIONS AND THEIR USES - Biocompatible and resorbable melt derived glass compositions which include: SiO | 02-16-2012 |
20120100217 | POLYMERIC MATERIAL - Disclosed herein is a polymeric material comprising a conductive polymer substantially homogeneously distributed within a hydrogel. Also disclosed are methods for making the polymeric material and uses for the polymeric material. | 04-26-2012 |
20120189698 | Pharmaceutical Dosage Forms for the Release of Active Compounds - Pharmaceutical form containing at least an active compound and a polymeric matrix, wherein said polymeric matrix comprises at least one polymer of cationic nature and at least one biodegradable polymer, process for the preparation thereof, pharmaceutical formulations comprising said pharmaceutical form, and their uses. The pharmaceutical form provides enhanced absorption of active compounds across the mucosa. | 07-26-2012 |
20120263792 | DUAL DRUG DOSAGE FORMS WITH IMPROVED SEPARATION OF DRUGS - Drug tablets that include a prolonged-release core and an immediate-release layer or shell are prepared with a thin barrier layer of drug-free polymer between the prolonged-release and immediate-release portions of the tablet. The barrier layer is penetrable by gastrointestinal fluid, thereby providing lull access of the gastrointestinal fluid to the prolonged-release core, but remains intact during the application of the immediate-release layer, substantially reducing or eliminating any penetration of the immediate-release drug into the prolonged-release portion. | 10-18-2012 |
20130059007 | Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes - A coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The drug-ion exchange resin complex is in admixture with a release retardant. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing this coated complex are described. | 03-07-2013 |
20130129827 | EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF PALIPERIDONE AND PROCESSES OF PREPARATION THEREOF - The present invention relates to extended release pharmaceutical compositions of paliperidone and process of preparation thereof. | 05-23-2013 |
20130142877 | PHARMACEUTICAL DOSAGE FORM COMPRISING ONE OR MORE ANTIRETROVIRAL ACTIVE INGREDIENTS - The invention relates to a pharmaceutical dosage form comprising one or more antiretroviral active ingredients in the form of a solid dispersion or solid solution in a matrix, wherein said matrix comprises an amino(meth)acrylate copolymer, characterized in that the matrix does not contain any essential amounts of pharmaceutically acceptable surfactants with an HLB value from 12 to 18 and in that the matrix comprises a mono carboxylic acid or an alcohol with 12 to 22 carbon atoms or both. | 06-06-2013 |
20130273162 | Oral Film Containing Opiate Enteric-Release Beads - A control release and abuse-resistant opiate drug delivery oral wafer or edible oral film dosage to treat pain and substance abuse is provided. The drug delivery oral wafer or edible oral film dosage includes a controlled release layer containing enteric-release beads dispersed in a polymer matrix. The enteric-release beads are formed from a therapeutic amount of an opioid agonist and/or pharmaceutically acceptable salt thereof and a sub-therapuetic amount of opioid antagonist and/or pharmaceutically acceptable salt thereof coated or encapsulated in an enteric-release polymer. The controlled release polymer matrix dissolves or disintegrates following administration or consumption of the oral wafer or edible oral film, releasing the enteric-release beads to be swallowed, with subsequent absorption of the active ingredients within the patient's intestines. | 10-17-2013 |
20140105979 | COMPOSITIONS AND METHODS FOR THE TRANSDERMAL DELIVERY OF METHYLPHENIDATE - Compositions for the transdermal delivery of methylphenidate in a flexible, finite form are described. The compositions comprise a polymer matrix that includes methylphenidate or a pharmaceutically acceptable salt and at least one acrylic polymer that is non-reactive with methylphenidate. Methods using the compositions to achieve transdermal delivery of methylphenidate or for treating Attention Deficit Disorder (ADD) and/or Attention Deficit/Hyperactivity Disorder (ADHD), postural orthostatic tachycardia syndrome, or narcolepsy also are described. | 04-17-2014 |
20140271866 | TRANSDERMAL DRUG DELIVERY SYSTEM CONTAINING RIVASTIGMINE - The present invention provides a transdermal drug delivery system comprising rivastigmine or its pharmaceutically acceptable salt and method of making the same. | 09-18-2014 |
20140294960 | IMPLANTABLE MODULAR HYDROGEL FOR SALIVARY GLAND RESTORATION - Implantable modular hydrogels to aid in salivary gland restoration and associated methods are provided. In one embodiment, the present disclosure provides for a hydrogel network comprising: a hyaluronic acid macromer crosslinked with a multiblock copolymer. | 10-02-2014 |
20150098997 | Methods and Compositions for Treating Attention Deficit Hyperactivity Disorder, Anxiety and Insomnia Using Dexmedetomidine Transdermal Compositions - Aspects of the invention include methods of treating ADHD, anxiety or insomnia by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver an amount of dexmedetomidine to a subject diagnosed as having ADHD, anxiety or insomnia. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine sufficient to treat ADHD, anxiety or insomnia in the subject. Also provided are transdermal delivery devices configured to deliver an amount of dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices. | 04-09-2015 |
20150297642 | COMPOSITIONS FOR THE RESTORATION OF A FECAL MICROBIOTA AND METHODS FOR MAKING AND USING THEM - In alternative embodiments, the invention provides compositions and methods for treating various disorders and conditions in mammals, including chronic disorders in which there is a presence of an abnormal microbiota or an abnormal distribution of microflora in the gastrointestinal tract. In alternative embodiments, the invention provides liquid preparations or formulations derived from a human fecal material (e.g., a stool) processed, e.g., filtered and/or centrifuged, such that all bacteria, fungal spores and viruses are removed, but retaining the native biologically active molecules from the fecal material and bacteriophages. In alternative embodiments, the invention provides a “rough-”, “incomplete-” or medium-filtered microbiota which still comprises native physiological components or nutritive agents for the bacteria, e.g., retains native biologically and nutritionally active components. In alternative embodiments, the invention provides a highly filtered or substantially purified microbiota in combination with, or having added back, a liquid preparation or formulation of the invention. In alternative embodiments, the invention provides compositions or formulations where the bacteria, or microbiota, component has been cultured, or cultured under anaerobic conditions, or harvested, stored and/or cultured under anaerobic conditions. In alternative embodiments, the invention provides various additives, compositions and donor restrictions for treating these disorders and conditions. | 10-22-2015 |
20160151357 | Pharmaceutical Formulation Containing Gelling Agent | 06-02-2016 |